Yuhan distributed gold rings to all employees

Immediately after CMA earlier this year, a gold ring engraved with LECLAZA was delivered

Marketing team of around 10 people, preparing for full-scale market entry in June

A gold ring recently issued by Yuhan to all employees.

 

LECLAZA is engraved on the outside of the ring

Yuhan recently handed out gold rings to former employees, showing Leclaza (Lazertinib)'s commitment to success.

 

According to the industry on the 11th, Yuhan provided a gold ring with LECLAZA to all employees at the end of last February.

 

It was only a month after receiving Conditional Marketing Authorization (CMA) as the 31st Korean drug on January 18th.

 

Yuhan's officials congratulated Leclaza for permission and wished for success in the future.

 

An official from Yuhan said, "A ring was distributed in commemoration of the achievement of the long-aspired work." He wished the success of Leclaza and gave the entire temple a gold ring.

 

Immediately after CMA earlier this year, a gold ring engraved with LECLAZA was delivered.

 

Formation of a marketing team of around 10 people, preparing for full-scale market entry in June Yuhan recently handed out gold rings to former employees, showing Leclaza (Lazertinib)'s commitment to success.

 

According to the industry on the 11th, Yuhan provided a gold ring with LECLAZA in English to all employees at the end of last February.

 

It was only a month after receiving Conditional Marketing Authorization (CMA) as the 31st Korean drug on January 18th.

 

Yuhan officials congratulated Leclaza for permission and wished for success in the future.

 

An official from Yuhan said, "A ring was distributed in commemoration of the achievement of the long-aspired work.

 

I know that the rings have been distributed to all employees as a means of encouraging the R&D department that has struggled with Leclaza permits, and at the same time supporting other departments that will lead Leclaza to success in the future." Another Yuhan official said, "Even though employees who have worked for 10 years or 20 years have received gold as a concept of long-term service, this is first time that all employees have given gold rings." Immediately after CMA earlier this year, a gold ring engraved with LECLAZA was delivered.

 

In addition to this, it is reported that the company is preparing for marketing in earnest by forming a dedicated Leclaza team.

 

Yuhan has formed a marketing team of about 10 people before and after the Leclaza license.

 

It is known that they are already conducting marketing to key doctors in general hospitals and hematologic oncology specialists.

 

The procedure for listing benefits is also going smoothly.

 

As soon as possible, it is expected to enter the market in earnest after being listed on the benefit list in June.

 

Leclaza was evaluated as appropriate as a benefit by the HIRA's Cancer Drugs Benefit Appraisal Committee on February 24, more than a month after CMA.

 

The committee is the first step to benefit.

 

On the 8th, the Pharmaceutical Benefits Advisory Committee recognized the appropriateness of the benefit, and even passed the second step.

 

The only remaining step is actually negotiating drug prices with the NHIS.

 

Yuhan plans to negotiate drug prices with the NHIS within the next 60 days.

 

After that, it is finally listed through the resolution of the Health Insurance Policy Committee of the MOHW.

 

Assuming that the drug price negotiations were successful, Leclaza took only 5 months from application to registration for the MFDS.

 

Other anticancer drugs took an average of 34 months from approval.

 

Leclaza was first approved as a second-line therapy for lung cancer in patients with EGFR T790M mutation-positive locally advanced or metastatic non-small cell lung cancer who had previously been treated with EGFR-TKI.

 

Based on the results of a phase 2 clinical trial (therapeutic exploratory clinical trial) conducted in Korea, it was approved under the condition that a phase 3 clinical trial should be conducted after marketing.

 

Currently, in Korea, the first-generation drug AstraZeneca's Iressa (Gefitinib), Roche's Tarceva (Erlotinib), and the second-generation drug Giotrif (Afatinib )and Vizimpro (Dacomitinib), and EGFR TKI such asTagrisso (Osimertinib) of AstraZeneca, a third-generation drug such as Leclaza, are being prescribed.